Henry Schein, Inc. (NASDAQ:HSIC) Stake Lessened by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina decreased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,395 shares of the company’s stock after selling 420 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Henry Schein were worth $3,833,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc grew its stake in Henry Schein by 274.6% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $32,000 after acquiring an additional 335 shares in the last quarter. Venturi Wealth Management LLC grew its position in Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock valued at $41,000 after purchasing an additional 569 shares in the last quarter. Quent Capital LLC increased its stake in Henry Schein by 91.2% in the 4th quarter. Quent Capital LLC now owns 677 shares of the company’s stock valued at $47,000 after buying an additional 323 shares during the period. Smartleaf Asset Management LLC lifted its position in Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after buying an additional 143 shares in the last quarter. Finally, City State Bank purchased a new position in shares of Henry Schein during the 4th quarter valued at $55,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Stock Down 2.0 %

Henry Schein stock opened at $64.28 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a fifty-two week low of $60.49 and a fifty-two week high of $82.49. The firm has a fifty day moving average price of $71.27 and a two-hundred day moving average price of $72.13. The firm has a market cap of $7.98 billion, a price-to-earnings ratio of 26.45, a P/E/G ratio of 2.13 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. Henry Schein’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.66 EPS. As a group, analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Insider Activity

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares of the company’s stock, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the transaction, the director now owns 24,805 shares in the company, valued at approximately $1,762,147.20. The trade was a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

HSIC has been the subject of a number of research reports. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $69.00 to $84.00 in a research report on Monday, January 6th. Wells Fargo & Company initiated coverage on Henry Schein in a report on Friday, February 14th. They set an “equal weight” rating and a $80.00 price target for the company. UBS Group dropped their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. StockNews.com upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Wednesday, April 9th. Finally, Jefferies Financial Group increased their price target on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.